Showing results (21-30 of 96) with videos related to
Sort By:
Pageof 10
Progress in Cardiovascular Diseases|April 11, 2021
Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypesAlberto Palazzuoli, Sergio Caravita, Stefania Paolillo, et al.Future Oncology (London, England)|December 21, 2012
Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literatureGiuseppina Gallucci, Alfredo Tartarone, Carlo Gabriele Tocchetti, et al.Circulation|September 4, 2003
Myocardial collagen turnover in hypertrophic cardiomyopathyRaffaella Lombardi, Sandro Betocchi, Maria Angela Losi, et al.International Journal of Cardiology|November 21, 2016
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyondDaniela Di Lisi, Rosalinda Madonna, Concetta Zito, et al.Current Heart Failure Reports|June 28, 2021
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical ManagementAlessandra Cuomo, Francesca Paudice, Giovanni D'Angelo, et al.Heart Failure Reviews|October 25, 2022
Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosisFrank L Dini, Nicola Riccardo Pugliese, Pietro Ameri, et al.Free Radical Biology & Medicine|April 30, 2021
Oxidative stress in anticancer therapies-related cardiac dysfunctionUmberto Attanasio, Flora Pirozzi, Remo Poto, et al.The American Journal of Cardiology|June 14, 2002
Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncopeFiore Manganelli, Sandro Betocchi, Quirino Ciampi, et al.ESC Heart Failure|November 24, 2020
Time-weighted lactate as a predictor of adverse outcome in acute heart failureGiorgio Bosso, Valentina Mercurio, Nermin Diab, et al.Stem Cells International|January 30, 2018
Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The BetrothedFabiana Passaro, Gianluca Testa, Luigi Ambrosone, et al.Pageof 10